BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1299 related articles for article (PubMed ID: 21623212)

  • 1. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Renal enhancement and excretion of the hepatobiliary contrast agent Gd-EOB-DTPA].
    Zangos S; Hammerstingl R; Mack MG; Straub R; Engelmann K; Eichler K; Balzer T; Vogl TJ
    Rofo; 2001 Nov; 173(11):1034-40. PubMed ID: 11704914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
    Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
    Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid.
    Jia J; Puls D; Oswald S; Jedlitschky G; Kühn JP; Weitschies W; Hosten N; Siegmund W; Keiser M
    Invest Radiol; 2014 Feb; 49(2):78-86. PubMed ID: 24056116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
    Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
    Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA.
    Tamada T; Ito K; Sone T; Yamamoto A; Yoshida K; Kakuba K; Tanimoto D; Higashi H; Yamashita T
    J Magn Reson Imaging; 2009 Mar; 29(3):636-40. PubMed ID: 19243060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phantom and animal studies of a new hepatobiliary agent for MR imaging: comparison of Gd-DTPA-DeA with Gd-EOB-DTPA.
    Yoshikawa K; Inoue Y; Akahane M; Shimada M; Itoh S; Seno A; Hayashi S
    J Magn Reson Imaging; 2003 Aug; 18(2):204-9. PubMed ID: 12884333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
    Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC
    Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatobiliary transit times of gadoxetate disodium (Primovist®) for protocol optimization of comprehensive MR imaging of the biliary system--what is normal?
    Ringe KI; Husarik DB; Gupta RT; Boll DT; Merkle EM
    Eur J Radiol; 2011 Aug; 79(2):201-5. PubMed ID: 20347540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA.
    Vogl TJ; Kümmel S; Hammerstingl R; Schellenbeck M; Schumacher G; Balzer T; Schwarz W; Müller PK; Bechstein WO; Mack MG; Söllner O; Felix R
    Radiology; 1996 Jul; 200(1):59-67. PubMed ID: 8657946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
    Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
    Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple and inexpensive system for controlling body temperature in small animal experiments using MRI and the effect of body temperature on the hepatic kinetics of Gd-EOB-DTPA.
    Murase K; Assanai P; Takata H; Saito S; Nishiura M
    Magn Reson Imaging; 2013 Dec; 31(10):1744-51. PubMed ID: 24094686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.
    Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K
    Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.
    Hamm B; Staks T; Mühler A; Bollow M; Taupitz M; Frenzel T; Wolf KJ; Weinmann HJ; Lange L
    Radiology; 1995 Jun; 195(3):785-92. PubMed ID: 7754011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers.
    Tamada T; Ito K; Higaki A; Yoshida K; Kanki A; Sato T; Higashi H; Sone T
    Eur J Radiol; 2011 Dec; 80(3):e311-6. PubMed ID: 21315529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential clinical factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhanced MR imaging.
    Higaki A; Tamada T; Sone T; Kanki A; Sato T; Tanimoto D; Higashi H; Ito K
    Magn Reson Imaging; 2012 Jun; 30(5):689-93. PubMed ID: 22459437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gd-EOB-DTPA as a functional MR cholangiography contrast agent: imaging gallbladder filling in patients with and without hepatobiliary dysfunction.
    Smith AD; Veniero JC
    J Comput Assist Tomogr; 2011; 35(4):439-45. PubMed ID: 21765298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement?
    Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Kitamura T; Araki T
    J Magn Reson Imaging; 2009 Nov; 30(5):1042-6. PubMed ID: 19856436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T2-weighted magnetic resonance imaging of the liver: evaluation of the effect in signal intensity after Gd-EOB-DTPA enhancement.
    Tamada T; Ito K; Yoshida K; Sone T; Murakami K; Kanki A; Watanabe S; Higashi H; Yamashita T
    J Comput Assist Tomogr; 2010; 34(2):182-6. PubMed ID: 20351500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast agent Gd-EOB-DTPA (EOB·Primovist®) for low-field magnetic resonance imaging of canine focal liver lesions.
    Yonetomi D; Kadosawa T; Miyoshi K; Nakao Y; Homma E; Hanazono K; Yamada E; Nakamura K; Ijiri A; Minegishi N; Maetani S; Hirayama K; Taniyama H; Nakade T
    Vet Radiol Ultrasound; 2012; 53(4):371-80. PubMed ID: 22548505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.